DT&CRO CO., Ltd. (KOSDAQ:383930)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,900.00
-15.00 (-0.38%)
At close: Jul 11, 2025, 3:30 PM KST
-55.17%
Market Cap50.75B
Revenue (ttm)39.50B
Net Income (ttm)-1.64B
Shares Out12.78M
EPS (ttm)-401.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,626
Average Volume72,135
Open3,915.00
Previous Close3,915.00
Day's Range3,895.00 - 3,955.00
52-Week Range3,675.00 - 9,900.00
Beta3.38
RSI44.13
Earnings Daten/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. It conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 383930
Full Company Profile

Financial Performance

In 2024, DT&CRO CO.'s revenue was 35.97 billion, an increase of 35.30% compared to the previous year's 26.59 billion. Losses were -2.00 billion, -87.98% less than in 2023.

Financial Statements

News

There is no news available yet.